Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $52.6 million.

  • Zenas BioPharma's Operating Expenses rose 2829.4% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.7 million, marking a year-over-year increase of 6212.5%. This contributed to the annual value of $168.9 million for FY2024, which is 9379.67% up from last year.
  • Zenas BioPharma's Operating Expenses amounted to $52.6 million in Q3 2025, which was up 2829.4% from $55.2 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Operating Expenses registered a high of $60.6 million during Q4 2024, and its lowest value of $14.4 million during Q3 2023.
  • In the last 3 years, Zenas BioPharma's Operating Expenses had a median value of $41.0 million in 2024 and averaged $40.3 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 18508.63% in 2024, then soared by 2829.4% in 2025.
  • Over the past 3 years, Zenas BioPharma's Operating Expenses (Quarter) stood at $24.8 million in 2023, then surged by 144.65% to $60.6 million in 2024, then dropped by 13.27% to $52.6 million in 2025.
  • Its Operating Expenses stands at $52.6 million for Q3 2025, versus $55.2 million for Q2 2025 and $47.3 million for Q1 2025.